Lovastatin. A preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidaemia.
about
The role of statins as potential targets for bone formationSimultaneous determination of simvastatin, lovastatin and niacin in human plasma by LC-MS/MS and its application to a human pharmacokinetic study.Pharmacology of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), including rosuvastatin and pitavastatin.Lipoprotein composition and oxidative modification during therapy with gemfibrozil and lovastatin in patients with combined hyperlipidaemia.Indications for lipid-lowering drugs.Systematic review of the in vitro effects of statins on oral and perioral microorganisms.Lovastatin and other HMG-CoA reductase inhibitors.HMG-CoA reductase inhibitors activate the unfolded protein response and induce cytoprotective GRP78 expression.Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.Statins: A new era in local drug deliveryNMR evaluation of total statin content and HMG-CoA reductase inhibition in red yeast rice (Monascus spp.) food supplements.Clinical effect of subgingivally delivered simvastatin in the treatment of patients with chronic periodontitis: a randomized clinical trial.[Severe rhabdomyolysis in a patient receiving lovastatin, danazol, and doxycycline]Pharmacokinetic interaction between propranolol and the HMG-CoA reductase inhibitors pravastatin and lovastatin.Comparative pharmacokinetics of lovastatin extended-release tablets and lovastatin immediate-release tablets in humans.Effects of policosanol and lovastatin in patients with intermittent claudication: a double-blind comparative pilot study.Statins induce suppressor of cytokine signaling-3 in macrophages.Pharmacokinetics and bioequivalence study of two tablet formulations of lovastatin in healthy volunteers.Consequences of blunting the mevalonate pathway in cancer identified by a pluri-omics approach.
P2860
Q24806198-5A6637E0-1058-44B8-A7D8-8149EB4F720BQ34019282-E0101BB6-078D-499F-A579-86B4BF59FD27Q34773911-B6973593-B4C2-49BB-B85F-7B196F348E09Q35802180-280659A8-2909-4EAC-9652-6CFA04370A91Q37743416-04845B62-57BC-4CC1-969A-3C0C4478166FQ38683382-396CA6AF-712D-42F5-859E-1D1FD280FDA7Q38740820-32471DBB-1EF0-4058-8BAA-9BF233736ED9Q39971963-5E915C5F-1A25-4301-B8E7-1E9990C399F9Q40921761-9EFF345E-623C-4748-B2E6-085916B50981Q41941641-3D0EE564-62DF-4C01-ACB2-84C2CD5DCA51Q42136536-E55DF1CB-0AA5-47D8-B8FA-C3304F317B87Q43164031-EE833D5D-0E7E-475C-A37D-ABE800F6D9D7Q43167348-61ADEDFF-548A-41F6-A755-3D8EE52761A1Q43205096-C6080DC4-C8D9-45FF-9FA1-CFE56B02D32EQ43878871-453F72C5-EA3A-439B-AB34-E980D2DBADF7Q44320171-DAFBB71C-80E3-4218-9F5C-9FCF1D36A239Q44673403-2CE0237F-BB6D-44D7-86DC-2D9F33E668AAQ46739223-B79C7A07-8F52-45F8-937B-7D7F3C85EAC0Q55433229-EC3E810D-2F49-4A80-9D79-4487BAA6576F
P2860
Lovastatin. A preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidaemia.
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
1988年论文
@zh
1988年论文
@zh-cn
name
Lovastatin. A preliminary revi ...... peutic use in hyperlipidaemia.
@en
Lovastatin. A preliminary revi ...... peutic use in hyperlipidaemia.
@nl
type
label
Lovastatin. A preliminary revi ...... peutic use in hyperlipidaemia.
@en
Lovastatin. A preliminary revi ...... peutic use in hyperlipidaemia.
@nl
prefLabel
Lovastatin. A preliminary revi ...... peutic use in hyperlipidaemia.
@en
Lovastatin. A preliminary revi ...... peutic use in hyperlipidaemia.
@nl
P1433
P1476
Lovastatin. A preliminary revi ...... peutic use in hyperlipidaemia.
@en
P2093
P304
P356
10.2165/00003495-198836040-00003
P577
1988-10-01T00:00:00Z
P6179
1050003179